Cell Biotech Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Myung-Jun Jung
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | no data |
CEO ownership | 25.4% |
Management average tenure | no data |
Board average tenure | no data |
Recent management updates
Recent updates
Shareholders Will Be Pleased With The Quality of Cell Biotech's (KOSDAQ:049960) Earnings
Aug 24Factors Income Investors Should Consider Before Adding Cell Biotech Co., Ltd. (KOSDAQ:049960) To Their Portfolio
May 05Is Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Recent Price Movement Underpinned By Its Weak Fundamentals?
Mar 18A Look At Cell Biotech's (KOSDAQ:049960) Share Price Returns
Feb 25Key Things To Watch Out For If You Are After Cell Biotech Co., Ltd.'s (KOSDAQ:049960) 3.2% Dividend
Feb 04Is Cell Biotech Co., Ltd. (KOSDAQ:049960) Popular Amongst Insiders?
Jan 14Don't Race Out To Buy Cell Biotech Co., Ltd. (KOSDAQ:049960) Just Because It's Going Ex-Dividend
Dec 24Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Dec 13Reflecting on Cell Biotech's (KOSDAQ:049960) Share Price Returns Over The Last Five Years
Nov 18CEO
Myung-Jun Jung (66 yo)
no data
Tenure
Dr. Myung-Jun Jung serves as the Chief Executive Officer of Cell Biotech Co. Ltd and served as its President. Dr. Jung served as Team Leader of Central Research Center at Daesang Corporation and Professor...
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/21 09:39 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cell Biotech Co., Ltd. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Young Ok Kim | DAOL Investment & Securities Co., Ltd. |
Hyuk Jin Yoon | Eugene Investment & Securities Co Ltd. |
Han Park | Hyundai Motor Securities Co. Ltd. |